News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
747,722 Results
Type
Article (53449)
Company Profile (458)
Press Release (693815)
Section
Business (216759)
Career Advice (2848)
Deals (37219)
Drug Delivery (114)
Drug Development (86659)
Employer Resources (181)
FDA (17067)
Job Trends (15874)
News (367892)
Policy (35472)
Tag
Academia (2894)
Alliances (53003)
Alzheimer's disease (1393)
Approvals (17002)
Artificial intelligence (202)
Bankruptcy (381)
Best Places to Work (12268)
Biotechnology (345)
Breast cancer (226)
Cancer (1683)
Cardiovascular disease (138)
Career advice (2383)
CAR-T (122)
Cell therapy (353)
Clinical research (69293)
Collaboration (650)
Compensation (317)
COVID-19 (2775)
C-suite (153)
Data (1548)
Diabetes (208)
Diagnostics (6579)
Earnings (87750)
Employer resources (157)
Events (118689)
Executive appointments (545)
FDA (17905)
Funding (575)
Gene therapy (253)
GLP-1 (730)
Government (4800)
Healthcare (20111)
Infectious disease (2878)
Inflammatory bowel disease (127)
Interviews (550)
IPO (17014)
Job creations (4075)
Job search strategy (1971)
Layoffs (487)
Legal (8692)
Lung cancer (251)
Manufacturing (238)
Medical device (13929)
Medtech (13934)
Mergers & acquisitions (20490)
Metabolic disorders (573)
Neuroscience (1817)
NextGen: Class of 2025 (7236)
Non-profit (4890)
Northern California (1960)
Obesity (328)
Opinion (238)
Patents (147)
People (61697)
Phase I (21592)
Phase II (30421)
Phase III (22661)
Pipeline (652)
Postmarket research (2931)
Preclinical (9265)
Radiopharmaceuticals (258)
Rare diseases (326)
Real estate (6411)
Regulatory (23722)
Research institute (2572)
Resumes & cover letters (453)
Southern California (1706)
Startups (3901)
United States (17978)
Vaccines (659)
Weight loss (245)
Date
Today (178)
Last 7 days (636)
Last 30 days (2718)
Last 365 days (36657)
2025 (2718)
2024 (37096)
2023 (41881)
2022 (53201)
2021 (57863)
2020 (56599)
2019 (49834)
2018 (37687)
2017 (34693)
2016 (34520)
2015 (40611)
2014 (34649)
2013 (29961)
2012 (31987)
2011 (32484)
2010 (30722)
Location
Africa (909)
Arizona (222)
Asia (42336)
Australia (7685)
California (4557)
Canada (1621)
China (383)
Colorado (203)
Connecticut (223)
Europe (94490)
Florida (643)
Georgia (157)
Illinois (471)
Indiana (257)
Maryland (743)
Massachusetts (3562)
Michigan (196)
Minnesota (338)
New Jersey (1278)
New York (1297)
North Carolina (897)
Northern California (1960)
Ohio (165)
Pennsylvania (1044)
South America (1289)
Southern California (1706)
Texas (666)
Utah (133)
Washington State (459)
747,722 Results for "tenax therapeutics formerly known as oxygen biotherapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Averna Therapeutics, formerly known as Exsilio Therapeutics, Appoints Thomas M. Barnes, Ph.D., as Chief Executive Officer
January 27, 2025
·
3 min read
Press Releases
Tenax Therapeutics Appoints Gillian Andor Vice President, Clinical Operations
January 22, 2025
·
4 min read
Bio NC
Tenax Therapeutics to Present at the 36th Annual Roth Conference
Tenax Therapeutics, Inc. today announced that it will participate in the 36th Annual Roth Conference in Dana Point, California, from March 17-19, 2024.
March 12, 2024
·
1 min read
Business
Tenax Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update
Tenax Therapeutics, Inc. (Nasdaq: TENX), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, announced financial results for the first quarter of 2024 and provided a corporate update.
May 14, 2024
·
11 min read
Business
Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results
Tenax Therapeutics, Inc. (Nasdaq: TENX) announced full year 2023 financial results, and provided clinical development and business updates.
March 28, 2024
·
11 min read
Bio NC
Tenax Therapeutics Announces Oral Presentation of Levosimendan for the Treatment of PH-HFpEF at THT 2024
Tenax Therapeutics, Inc. today announced Dr. Sanjiv Shah will present data and review the scientific basis for the use of levosimendan in PH-HFpEF.
February 29, 2024
·
5 min read
Bio NC
Tenax Therapeutics to Host KOL Event: “LEVEL Setting: the Scientific Rationale for Levosimendan as a Potential First Treatment for PH-HFpEF, and the Ongoing Phase 3 LEVEL Study”
Tenax Therapeutics, Inc. today announced that Stuart Rich, Tenax CMO, will moderate ”LEVEL Setting,” a scientific round-table exploration of the rationale for TNX-103 (oral levosimendan), for the treatment of PH-HFpEF.
April 9, 2024
·
9 min read
Press Releases
Tenax Therapeutics to Present at the Guggenheim Healthcare Innovation Conference
November 1, 2024
·
1 min read
Drug Development
Tenax Therapeutics Announces Global License Amendment that Significantly Expands Rights to Levosimendan
Tenax Therapeutics, Inc. today announced it has secured global development, commercial, and IP rights to oral and subcutaneous levosimendan for the treatment of pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF).
February 20, 2024
·
6 min read
Press Releases
Tenax Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
November 13, 2024
·
8 min read
1 of 74,773
Next
